We are searching data for your request:
Upon completion, a link will appear to access the found materials.
I was reading about Cas1 and Cas2 and came across this excerpt:
… Cas2 was identified as a metal-dependent endoribonuclease that cleaves ssRNA or dsDNA…
What does metal-dependent mean in this context?
It means that these enzymes need a metal ion as a co-factor for their function. This metal ion is typically bound somewhere near or in the active center and helps stabilizing transition states.
Without these metals, these enzymes cannot function properly, that's why chelating agents are used in protein or DNA preparations to inhibit their function.
- Information available at cut rates: structure and mechanism of ribonucleases.
- The Role of Metals in Enzyme Activity
What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges
Monoclonal B-cell lymphocytosis (MBL) is defined as a laboratory abnormality where small (<5 x 10(9)/L) clonal B-cell populations are detected in the peripheral blood of otherwise healthy subjects. According to the immunophenotype, MBL is labeled as chronic lymphocytic leukemia (CLL)-like (75% of cases), atypical CLL, and CD5-negative. Concentration of clonal B cells differentiates low- (LC) and high-count (HC)-MBL (< or ≥ 0.5 x 10(9)/L, respectively). Thanks to technical improvements, we are able to identify CLL-like clonal B-cell populations at increased frequency with age, but we are still far from understanding its relationship with clinically overt CLL. LC-MBL, requiring high-throughput screening technique to be identified in population studies, seems to be a bird of a different feather and several hints suggest that LC-MBL is related to aging and/or chronic antigenic stimulation. Immunogenetic, cytogenetic and genetic data support the notion that HC-MBL, usually identified in the clinical setting, is a premalignant condition and, based on biological parameters, it is frequently difficult to differentiate it from early stage CLL. The rapid improvement and widespread availability of cutting-edge technology, in particular next-generation sequencing (NGS), raises hope that we are getting closer to unveiling the fundamental nature of MBL and CLL and how they are related to each other.
Keywords: Chronic lymphocytic leukemia Cytogenetic Immunoglobulin genes Monoclonal B-cell lymphocytosis Next-generation sequencing.
14th century, in the meaning defined at sense 1a
Middle English progenitour, borrowed from Anglo-French & Latin Anglo-French, borrowed from Latin prōgenitor "individual from whom a person or family is descended, ancestor," agentive derivative of prōgignere "to produce as offspring, bring into being, give rise to" (from prō- pro- entry 2 + gignere "to bring into being, beget, give birth to"), after genitor "father, parent, originator," going back to Indo-European *ǵenh1- "engender, beget" + *-tor/*-tōr, agent suffix, from which also Greek genétōr "father, begetter, ancestor," Sanskrit janitar-, janitá "father, progenitor" — more at kin entry 1
Note: Alternatively genitor has been explained as a new formation based on genitus, past participle of gignere. The older and still somewhat more attractive view sees genitus as the new formation, based on the perfect genuī or on genitor itself, after the connection with the original verbal adjective (g)nātus (going back to zero-grade *ǵn̥h1-to-) became weakened.
Repeated sequences Edit
The discovery of clustered DNA repeats occurred independently in three parts of the world. The first description of what would later be called CRISPR is from Osaka University researcher Yoshizumi Ishino and his colleagues in 1987. They accidentally cloned part of a CRISPR sequence together with the "iap" gene (isozyme conversion of alkaline phosphatase) from the genome of Escherichia coli   that was their target. The organization of the repeats was unusual. Repeated sequences are typically arranged consecutively, without interspersed different sequences.   They did not know the function of the interrupted clustered repeats.
In 1993, researchers of Mycobacterium tuberculosis in the Netherlands published two articles about a cluster of interrupted direct repeats (DR) in that bacterium. They recognized the diversity of the sequences that intervened the direct repeats among different strains of M. tuberculosis  and used this property to design a typing method that was named spoligotyping, which is still in use today.  
Francisco Mojica at the University of Alicante in Spain studied repeats observed in the archaeal organisms of Haloferax and Haloarcula species, and their function. Mojica's supervisor surmised at the time that the clustered repeats had a role in correctly segregating replicated DNA into daughter cells during cell division because plasmids and chromosomes with identical repeat arrays could not coexist in Haloferax volcanii. Transcription of the interrupted repeats was also noted for the first time this was the first full characterization of CRISPR.   By 2000, Mojica performed a survey of scientific literature and one of his students performed a search in published genomes with a program devised by himself. They identified interrupted repeats in 20 species of microbes as belonging to the same family.  In 2001, Mojica and Ruud Jansen, who were searching for additional interrupted repeats, proposed the acronym CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to alleviate the confusion stemming from the numerous acronyms used to describe the sequences in the scientific literature.   In 2002, Tang, et al. showed evidence that CRISPR repeat regions from the genome of Archaeoglobus fulgidus were transcribed into long RNA molecules that were subsequently processed into unit-length small RNAs, plus some longer forms of 2, 3, or more spacer-repeat units.  
In 2005, yogurt researcher Rodolphe Barrangou, discovered that Streptococcus thermophilus, after iterative phage challenges, develops increased phage resistance, and this enhanced resistance is due to incorporation of additional CRISPR spacer sequences.  The Danish food company Danisco, which at that time Barrangou worked for, then developed phage resistant S. thermophilus strains for use in yogurt production. Danisco was later bought out by DuPont, which "owns about 50 percent of the global dairy culture market" and the technology went mainstream. 
CRISPR-associated systems Edit
A major addition to the understanding of CRISPR came with Jansen's observation that the prokaryote repeat cluster was accompanied by a set of homologous genes that make up CRISPR-associated systems or cas genes. Four cas genes (cas 1–4) were initially recognized. The Cas proteins showed helicase and nuclease motifs, suggesting a role in the dynamic structure of the CRISPR loci.  In this publication the acronym CRISPR was used as the universal name of this pattern. However, the CRISPR function remained enigmatic.
In 2005, three independent research groups showed that some CRISPR spacers are derived from phage DNA and extrachromosomal DNA such as plasmids.    In effect, the spacers are fragments of DNA gathered from viruses that previously tried to attack the cell. The source of the spacers was a sign that the CRISPR/cas system could have a role in adaptive immunity in bacteria.   All three studies proposing this idea were initially rejected by high-profile journals, but eventually appeared in other journals. 
The first publication  proposing a role of CRISPR-Cas in microbial immunity, by Mojica and collaborators at the University of Alicante, predicted a role for the RNA transcript of spacers on target recognition in a mechanism that could be analogous to the RNA interference system used by eukaryotic cells. Koonin and colleagues extended this RNA interference hypothesis by proposing mechanisms of action for the different CRISPR-Cas subtypes according to the predicted function of their proteins. 
Experimental work by several groups revealed the basic mechanisms of CRISPR-Cas immunity. In 2007, the first experimental evidence that CRISPR was an adaptive immune system was published.   A CRISPR region in Streptococcus thermophilus acquired spacers from the DNA of an infecting bacteriophage. The researchers manipulated the resistance of S. thermophilus to different types of phage by adding and deleting spacers whose sequence matched those found in the tested phages.   In 2008, Brouns and Van der Oost identified a complex of Cas proteins (called Cascade) that in E. coli cut the CRISPR RNA precursor within the repeats into mature spacer-containing RNA molecules called CRISPR RNA (crRNA), which remained bound to the protein complex.  Moreover, it was found that Cascade, crRNA and a helicase/nuclease (Cas3) were required to provide a bacterial host with immunity against infection by a DNA virus. By designing an anti-virus CRISPR, they demonstrated that two orientations of the crRNA (sense/antisense) provided immunity, indicating that the crRNA guides were targeting dsDNA. That year Marraffini and Sontheimer confirmed that a CRISPR sequence of S. epidermidis targeted DNA and not RNA to prevent conjugation. This finding was at odds with the proposed RNA-interference-like mechanism of CRISPR-Cas immunity, although a CRISPR-Cas system that targets foreign RNA was later found in Pyrococcus furiosus.   A 2010 study showed that CRISPR-Cas cuts both strands of phage and plasmid DNA in S. thermophilus. 
Researchers studied a simpler CRISPR system from Streptococcus pyogenes that relies on the protein Cas9. The Cas9 endonuclease is a four-component system that includes two small molecules: crRNA and trans-activating CRISPR RNA (tracrRNA).   Jennifer Doudna and Emmanuelle Charpentier re-engineered the Cas9 endonuclease into a more manageable two-component system by fusing the two RNA molecules into a "single-guide RNA" that, when combined with Cas9, could find and cut the DNA target specified by the guide RNA. This contribution was so significant that it was recognized by the Nobel Prize in Chemistry in 2020. By manipulating the nucleotide sequence of the guide RNA, the artificial Cas9 system could be programmed to target any DNA sequence for cleavage.  Another group of collaborators comprising Virginijus Šikšnys together with Gasiūnas, Barrangou and Horvath showed that Cas9 from the S. thermophilus CRISPR system can also be reprogrammed to target a site of their choosing by changing the sequence of its crRNA. These advances fueled efforts to edit genomes with the modified CRISPR-Cas9 system. 
Groups led by Feng Zhang and George Church simultaneously published descriptions of genome editing in human cell cultures using CRISPR-Cas9 for the first time.    It has since been used in a wide range of organisms, including baker's yeast (Saccharomyces cerevisiae),    the opportunistic pathogen Candida albicans,   zebrafish (Danio rerio),  fruit flies (Drosophila melanogaster),   ants (Harpegnathos saltator  and Ooceraea biroi  ), mosquitoes (Aedes aegypti  ), nematodes (Caenorhabditis elegans),  plants,  mice,   monkeys  and human embryos. 
CRISPR has been modified to make programmable transcription factors that allow scientists to target and activate or silence specific genes. 
The CRISPR-Cas9 system has shown to make effective gene edits in Human tripronuclear zygotes first described in a 2015 paper by Chinese scientists P. Liang and Y. Xu. The system made a successful cleavage of mutant Beta-Hemoglobin (HBB) in 28 out of 54 embryos. 4 out of the 28 embryos were successfully recombined using a donor template given by the scientists. The scientists showed that during DNA recombination of the cleaved strand, the homologous endogenous sequence HBD competes with the exogenous donor template. DNA repair in human embryos is much more complicated and particular than in derived stem cells. 
Cas12a (formerly Cpf1) Edit
In 2015, the nuclease Cas12a (formerly known as Cpf1  ) was characterized in the CRISPR/Cpf1 system of the bacterium Francisella novicida.   Its original name, from a TIGRFAMs protein family definition built in 2012, reflects the prevalence of its CRISPR-Cas subtype in the Prevotella and Francisella lineages. Cas12a showed several key differences from Cas9 including: causing a 'staggered' cut in double stranded DNA as opposed to the 'blunt' cut produced by Cas9, relying on a 'T rich' PAM (providing alternative targeting sites to Cas9) and requiring only a CRISPR RNA (crRNA) for successful targeting. By contrast Cas9 requires both crRNA and a transactivating crRNA (tracrRNA).
These differences may give Cas12a some advantages over Cas9. For example, Cas12a's small crRNAs are ideal for multiplexed genome editing, as more of them can be packaged in one vector than can Cas9's sgRNAs. As well, the sticky 5′ overhangs left by Cas12a can be used for DNA assembly that is much more target-specific than traditional Restriction Enzyme cloning.  Finally, Cas12a cleaves DNA 18–23 base pairs downstream from the PAM site. This means there is no disruption to the recognition sequence after repair, and so Cas12a enables multiple rounds of DNA cleavage. By contrast, since Cas9 cuts only 3 base pairs upstream of the PAM site, the NHEJ pathway results in indel mutations that destroy the recognition sequence, thereby preventing further rounds of cutting. In theory, repeated rounds of DNA cleavage should cause an increased opportunity for the desired genomic editing to occur.  A distinctive feature of Cas12a, as compared to Cas9, is that after cutting its target, Cas12a remains bound to the target and then cleaves other ssDNA molecules non-discriminately.  This property is called "collateral cleavage" or "trans-cleavage" activity and has been exploited for the development of various diagnostic technologies.  
Cas13 (formerly C2c2) Edit
In 2016, the nuclease Cas13a (formerly known as C2c2) from the bacterium Leptotrichia shahii was characterized. Cas13 is an RNA-guided RNA endonuclease, which means that it does not cleave DNA, but only single-stranded RNA. Cas13 is guided by its crRNA to a ssRNA target and binds and cleaves the target. Similar to Cas12a, the Cas13 remains bound to the target and then cleaves other ssRNA molecules non-discriminately.  This collateral cleavage property has been exploited for the development of various diagnostic technologies.   
Repeats and spacers Edit
The CRISPR array is made up of an AT-rich leader sequence followed by short repeats that are separated by unique spacers.  CRISPR repeats typically range in size from 28 to 37 base pairs (bps), though there can be as few as 23 bp and as many as 55 bp.  Some show dyad symmetry, implying the formation of a secondary structure such as a stem-loop ('hairpin') in the RNA, while others are designed to be unstructured. The size of spacers in different CRISPR arrays is typically 32 to 38 bp (range 21 to 72 bp).  New spacers can appear rapidly as part of the immune response to phage infection.  There are usually fewer than 50 units of the repeat-spacer sequence in a CRISPR array. 
CRISPR RNA structures Edit
Cas genes and CRISPR subtypes Edit
Small clusters of cas genes are often located next to CRISPR repeat-spacer arrays. Collectively the 93 cas genes are grouped into 35 families based on sequence similarity of the encoded proteins. 11 of the 35 families form the cas core, which includes the protein families Cas1 through Cas9. A complete CRISPR-Cas locus has at least one gene belonging to the cas core. 
CRISPR-Cas systems fall into two classes. Class 1 systems use a complex of multiple Cas proteins to degrade foreign nucleic acids. Class 2 systems use a single large Cas protein for the same purpose. Class 1 is divided into types I, III, and IV class 2 is divided into types II, V, and VI.  The 6 system types are divided into 19 subtypes.  Each type and most subtypes are characterized by a "signature gene" found almost exclusively in the category. Classification is also based on the complement of cas genes that are present. Most CRISPR-Cas systems have a Cas1 protein. The phylogeny of Cas1 proteins generally agrees with the classification system.  Many organisms contain multiple CRISPR-Cas systems suggesting that they are compatible and may share components.   The sporadic distribution of the CRISPR/Cas subtypes suggests that the CRISPR/Cas system is subject to horizontal gene transfer during microbial evolution.
CRISPR-Cas immunity is a natural process of bacteria and archaea.  CRISPR-Cas prevents bacteriophage infection, conjugation and natural transformation by degrading foreign nucleic acids that enter the cell. 
Spacer acquisition Edit
When a microbe is invaded by a bacteriophage, the first stage of the immune response is to capture phage DNA and insert it into a CRISPR locus in the form of a spacer. Cas1 and Cas2 are found in both types of CRISPR-Cas immune systems, which indicates that they are involved in spacer acquisition. Mutation studies confirmed this hypothesis, showing that removal of cas1 or cas2 stopped spacer acquisition, without affecting CRISPR immune response.     
Multiple Cas1 proteins have been characterised and their structures resolved.    Cas1 proteins have diverse amino acid sequences. However, their crystal structures are similar and all purified Cas1 proteins are metal-dependent nucleases/integrases that bind to DNA in a sequence-independent manner.  Representative Cas2 proteins have been characterised and possess either (single strand) ssRNA-  or (double strand) dsDNA-   specific endoribonuclease activity.
In the I-E system of E. coli Cas1 and Cas2 form a complex where a Cas2 dimer bridges two Cas1 dimers.  In this complex Cas2 performs a non-enzymatic scaffolding role,  binding double-stranded fragments of invading DNA, while Cas1 binds the single-stranded flanks of the DNA and catalyses their integration into CRISPR arrays.    New spacers are usually added at the beginning of the CRISPR next to the leader sequence creating a chronological record of viral infections.  In E. coli a histone like protein called integration host factor (IHF), which binds to the leader sequence, is responsible for the accuracy of this integration.  IHF also enhances integration efficiency in the type I-F system of Pectobacterium atrosepticum.  but in other systems different host factors may be required 
Protospacer adjacent motifs Edit
Bioinformatic analysis of regions of phage genomes that were excised as spacers (termed protospacers) revealed that they were not randomly selected but instead were found adjacent to short (3–5 bp) DNA sequences termed protospacer adjacent motifs (PAM). Analysis of CRISPR-Cas systems showed PAMs to be important for type I and type II, but not type III systems during acquisition.       In type I and type II systems, protospacers are excised at positions adjacent to a PAM sequence, with the other end of the spacer cut using a ruler mechanism, thus maintaining the regularity of the spacer size in the CRISPR array.   The conservation of the PAM sequence differs between CRISPR-Cas systems and appears to be evolutionarily linked to Cas1 and the leader sequence.  
New spacers are added to a CRISPR array in a directional manner,  occurring preferentially,      but not exclusively, adjacent   to the leader sequence. Analysis of the type I-E system from E. coli demonstrated that the first direct repeat adjacent to the leader sequence, is copied, with the newly acquired spacer inserted between the first and second direct repeats.  
The PAM sequence appears to be important during spacer insertion in type I-E systems. That sequence contains a strongly conserved final nucleotide (nt) adjacent to the first nt of the protospacer. This nt becomes the final base in the first direct repeat.    This suggests that the spacer acquisition machinery generates single-stranded overhangs in the second-to-last position of the direct repeat and in the PAM during spacer insertion. However, not all CRISPR-Cas systems appear to share this mechanism as PAMs in other organisms do not show the same level of conservation in the final position.  It is likely that in those systems, a blunt end is generated at the very end of the direct repeat and the protospacer during acquisition.
Insertion variants Edit
Analysis of Sulfolobus solfataricus CRISPRs revealed further complexities to the canonical model of spacer insertion, as one of its six CRISPR loci inserted new spacers randomly throughout its CRISPR array, as opposed to inserting closest to the leader sequence. 
Multiple CRISPRs contain many spacers to the same phage. The mechanism that causes this phenomenon was discovered in the type I-E system of E. coli. A significant enhancement in spacer acquisition was detected where spacers already target the phage, even mismatches to the protospacer. This ‘priming’ requires the Cas proteins involved in both acquisition and interference to interact with each other. Newly acquired spacers that result from the priming mechanism are always found on the same strand as the priming spacer.    This observation led to the hypothesis that the acquisition machinery slides along the foreign DNA after priming to find a new protospacer. 
CRISPR-RNA (crRNA), which later guides the Cas nuclease to the target during the interference step, must be generated from the CRISPR sequence. The crRNA is initially transcribed as part of a single long transcript encompassing much of the CRISPR array.  This transcript is then cleaved by Cas proteins to form crRNAs. The mechanism to produce crRNAs differs among CRISPR/Cas systems. In type I-E and type I-F systems, the proteins Cas6e and Cas6f respectively, recognise stem-loops    created by the pairing of identical repeats that flank the crRNA.  These Cas proteins cleave the longer transcript at the edge of the paired region, leaving a single crRNA along with a small remnant of the paired repeat region.
Type III systems also use Cas6, however their repeats do not produce stem-loops. Cleavage instead occurs by the longer transcript wrapping around the Cas6 to allow cleavage just upstream of the repeat sequence.   
Type II systems lack the Cas6 gene and instead utilize RNaseIII for cleavage. Functional type II systems encode an extra small RNA that is complementary to the repeat sequence, known as a trans-activating crRNA (tracrRNA).  Transcription of the tracrRNA and the primary CRISPR transcript results in base pairing and the formation of dsRNA at the repeat sequence, which is subsequently targeted by RNaseIII to produce crRNAs. Unlike the other two systems the crRNA does not contain the full spacer, which is instead truncated at one end. 
CrRNAs associate with Cas proteins to form ribonucleotide complexes that recognize foreign nucleic acids. CrRNAs show no preference between the coding and non-coding strands, which is indicative of an RNA-guided DNA-targeting system.        The type I-E complex (commonly referred to as Cascade) requires five Cas proteins bound to a single crRNA.  
During the interference stage in type I systems the PAM sequence is recognized on the crRNA-complementary strand and is required along with crRNA annealing. In type I systems correct base pairing between the crRNA and the protospacer signals a conformational change in Cascade that recruits Cas3 for DNA degradation.
Type II systems rely on a single multifunctional protein, Cas9, for the interference step.  Cas9 requires both the crRNA and the tracrRNA to function and cleaves DNA using its dual HNH and RuvC/RNaseH-like endonuclease domains. Basepairing between the PAM and the phage genome is required in type II systems. However, the PAM is recognized on the same strand as the crRNA (the opposite strand to type I systems).
Type III systems, like type I require six or seven Cas proteins binding to crRNAs.   The type III systems analysed from S. solfataricus and P. furiosus both target the mRNA of phages rather than phage DNA genome,   which may make these systems uniquely capable of targeting RNA-based phage genomes.  Type III systems were also found to target DNA in addition to RNA using a different Cas protein in the complex, Cas10.  The DNA cleavage was shown to be transcription dependent. 
The mechanism for distinguishing self from foreign DNA during interference is built into the crRNAs and is therefore likely common to all three systems. Throughout the distinctive maturation process of each major type, all crRNAs contain a spacer sequence and some portion of the repeat at one or both ends. It is the partial repeat sequence that prevents the CRISPR-Cas system from targeting the chromosome as base pairing beyond the spacer sequence signals self and prevents DNA cleavage.  RNA-guided CRISPR enzymes are classified as type V restriction enzymes.
The cas genes in the adaptor and effector modules of the CRISPR-Cas system are believed to have evolved from two different ancestral modules. A transposon-like element called casposon encoding the Cas1-like integrase and potentially other components of the adaptation module was inserted next to the ancestral effector module, which likely functioned as an independent innate immune system.  The highly conserved cas1 and cas2 genes of the adaptor module evolved from the ancestral module while a variety of class 1 effector cas genes evolved from the ancestral effector module.  The evolution of these various class 1 effector module cas genes was guided by various mechanisms, such as duplication events.  On the other hand, each type of class 2 effector module arose from subsequent independent insertions of mobile genetic elements.  These mobile genetic elements took the place of the multiple gene effector modules to create single gene effector modules that produce large proteins which perform all the necessary tasks of the effector module.  The spacer regions of CRISPR-Cas systems are taken directly from foreign mobile genetic elements and thus their long term evolution is hard to trace.  The non-random evolution of these spacer regions has been found to be highly dependent on the environment and the particular foreign mobile genetic elements it contains. 
CRISPR/Cas can immunize bacteria against certain phages and thus halt transmission. For this reason, Koonin described CRISPR/Cas as a Lamarckian inheritance mechanism.  However, this was disputed by a critic who noted, "We should remember [Lamarck] for the good he contributed to science, not for things that resemble his theory only superficially. Indeed, thinking of CRISPR and other phenomena as Lamarckian only obscures the simple and elegant way evolution really works".  But as more recent studies have been conducted, it has become apparent that the acquired spacer regions of CRISPR-Cas systems are indeed a form of Lamarckian evolution because they are genetic mutations that are acquired and then passed on.  On the other hand, the evolution of the Cas gene machinery that facilitates the system evolves through classic Darwinian evolution. 
Analysis of CRISPR sequences revealed coevolution of host and viral genomes.  Cas9 proteins are highly enriched in pathogenic and commensal bacteria. CRISPR/Cas-mediated gene regulation may contribute to the regulation of endogenous bacterial genes, particularly during interaction with eukaryotic hosts. For example, Francisella novicida uses a unique, small, CRISPR/Cas-associated RNA (scaRNA) to repress an endogenous transcript encoding a bacterial lipoprotein that is critical for F. novicida to dampen host response and promote virulence. 
The basic model of CRISPR evolution is newly incorporated spacers driving phages to mutate their genomes to avoid the bacterial immune response, creating diversity in both the phage and host populations. To resist a phage infection, the sequence of the CRISPR spacer must correspond perfectly to the sequence of the target phage gene. Phages can continue to infect their hosts given point mutations in the spacer.  Similar stringency is required in PAM or the bacterial strain remains phage sensitive.  
A study of 124 S. thermophilus strains showed that 26% of all spacers were unique and that different CRISPR loci showed different rates of spacer acquisition.  Some CRISPR loci evolve more rapidly than others, which allowed the strains' phylogenetic relationships to be determined. A comparative genomic analysis showed that E. coli and S. enterica evolve much more slowly than S. thermophilus. The latter's strains that diverged 250 thousand years ago still contained the same spacer complement. 
Metagenomic analysis of two acid-mine-drainage biofilms showed that one of the analyzed CRISPRs contained extensive deletions and spacer additions versus the other biofilm, suggesting a higher phage activity/prevalence in one community than the other.  In the oral cavity, a temporal study determined that 7–22% of spacers were shared over 17 months within an individual while less than 2% were shared across individuals. 
From the same environment a single strain was tracked using PCR primers specific to its CRISPR system. Broad-level results of spacer presence/absence showed significant diversity. However, this CRISPR added 3 spacers over 17 months,  suggesting that even in an environment with significant CRISPR diversity some loci evolve slowly.
CRISPRs were analysed from the metagenomes produced for the human microbiome project.  Although most were body-site specific, some within a body site are widely shared among individuals. One of these loci originated from streptococcal species and contained ≈15,000 spacers, 50% of which were unique. Similar to the targeted studies of the oral cavity, some showed little evolution over time. 
CRISPR evolution was studied in chemostats using S. thermophilus to directly examine spacer acquisition rates. In one week, S. thermophilus strains acquired up to three spacers when challenged with a single phage.  During the same interval the phage developed single nucleotide polymorphisms that became fixed in the population, suggesting that targeting had prevented phage replication absent these mutations. 
Another S. thermophilus experiment showed that phages can infect and replicate in hosts that have only one targeting spacer. Yet another showed that sensitive hosts can exist in environments with high phage titres.  The chemostat and observational studies suggest many nuances to CRISPR and phage (co)evolution.
CRISPRs are widely distributed among bacteria and archaea  and show some sequence similarities.  Their most notable characteristic is their repeating spacers and direct repeats. This characteristic makes CRISPRs easily identifiable in long sequences of DNA, since the number of repeats decreases the likelihood of a false positive match. 
Analysis of CRISPRs in metagenomic data is more challenging, as CRISPR loci do not typically assemble, due to their repetitive nature or through strain variation, which confuses assembly algorithms. Where many reference genomes are available, polymerase chain reaction (PCR) can be used to amplify CRISPR arrays and analyse spacer content.       However, this approach yields information only for specifically targeted CRISPRs and for organisms with sufficient representation in public databases to design reliable polymerase chain reaction (PCR) primers. Degenerate repeat-specific primers can be used to amplify CRISPR spacers directly from environmental samples amplicons containing two or three spacers can be then computationally assembled to reconstruct long CRISPR arrays. 
The alternative is to extract and reconstruct CRISPR arrays from shotgun metagenomic data. This is computationally more difficult, particularly with second generation sequencing technologies (e.g. 454, Illumina), as the short read lengths prevent more than two or three repeat units appearing in a single read. CRISPR identification in raw reads has been achieved using purely de novo identification  or by using direct repeat sequences in partially assembled CRISPR arrays from contigs (overlapping DNA segments that together represent a consensus region of DNA)  and direct repeat sequences from published genomes  as a hook for identifying direct repeats in individual reads.
Another way for bacteria to defend against phage infection is by having chromosomal islands. A subtype of chromosomal islands called phage-inducible chromosomal island (PICI) is excised from a bacterial chromosome upon phage infection and can inhibit phage replication.  PICIs are induced, excised, replicated and finally packaged into small capsids by certain staphylococcal temperate phages. PICIs use several mechanisms to block phage reproduction. In first mechanism PICI-encoded Ppi differentially blocks phage maturation by binding or interacting specifically with phage TerS, hence blocks phage TerS/TerL complex formation responsible for phage DNA packaging. In second mechanism PICI CpmAB redirect the phage capsid morphogenetic protein to make 95% of SaPI-sized capsid and phage DNA can package only 1/3rd of their genome in these small capsid and hence become nonviable phage.  The third mechanism involves two proteins, PtiA and PtiB, that target the LtrC, which is responsible for the production of virion and lysis proteins. This interference mechanism is modulated by a modulatory protein, PtiM, binds to one of the interference-mediating proteins, PtiA, and hence achieving the required level of interference. 
One study showed that lytic ICP1 phage, which specifically targets Vibrio cholerae serogroup O1, has acquired a CRISPR/Cas system that targets a V. cholera PICI-like element. The system has 2 CRISPR loci and 9 Cas genes. It seems to be homologous to the I-F system found in Yersinia pestis. Moreover, like the bacterial CRISPR/Cas system, ICP1 CRISPR/Cas can acquire new sequences, which allows phage and host to co-evolve. 
Certain archaeal viruses were shown to carry mini-CRISPR arrays containing one or two spacers. It has been shown that spacers within the virus-borne CRISPR arrays target other viruses and plasmids, suggesting that mini-CRISPR arrays represent a mechanism of heterotypic superinfection exclusion and participate in interviral conflicts. 
CRISPR gene editing Edit
CRISPR technology has been applied in the food and farming industries to engineer probiotic cultures and to immunize industrial cultures (for yogurt, for instance) against infections. It is also being used in crops to enhance yield, drought tolerance and nutritional value. 
By the end of 2014 some 1000 research papers had been published that mentioned CRISPR.   The technology had been used to functionally inactivate genes in human cell lines and cells, to study Candida albicans, to modify yeasts used to make biofuels and to genetically modify crop strains.  Hsu and his colleagues state that the ability to manipulate the genetic sequences allows for reverse engineering that can positively affect biofuel production  CRISPR can also be used to change mosquitos so they cannot transmit diseases such as malaria.  CRISPR-based approaches utilizing Cas12a have recently been utilized in the successful modification of a broad number of plant species. 
In July 2019, CRISPR was used to experimentally treat a patient with a genetic disorder. The patient was a 34-year-old woman with sickle cell disease. 
In February 2020, progress was made on HIV treatments with 60-80% of the DNA removed in mice and some being completely free from the virus after edits involving both LASER ART, a new anti-retroviral therapy, and CRISPR. 
In March 2020, CRISPR-modified virus was injected into a patient's eye in an attempt to treat Leber congenital amaurosis. 
In the future, CRISPR gene editing could potentially be used to create new species or revive extinct species from closely related ones. 
CRISPR-based re-evaluations of claims for gene-disease relationships have led to the discovery of potentially important anomalies. 
CRISPR as diagnostic tool Edit
CRISPR associated nucleases have shown to be useful as a tool for molecular testing due to their ability to specifically target nucleic acid sequences in a high background of non-target sequences. In 2016, the Cas9 nuclease was used to deplete unwanted nucleotide sequences in next-generation sequencing libraries while requiring only 250 picograms of initial RNA input.  Beginning in 2017, CRISPR associated nucleases were also used for direct diagnostic testing of nucleic acids, down to single molecule sensitivity.  
By coupling CRISPR-based diagnostics to additional enzymatic processes, the detection of molecules beyond nucleic acids is possible. One example of a coupled technology is SHERLOCK-based Profiling of IN vitro Transcription (SPRINT). SPRINT can be used to detect a variety of substances, such as metabolites in patient samples or contaminants in environmental samples, with high throughput or with portable point-of-care devices.  CRISPR/Cas platforms are also being explored for detection      and inactivation of SARS-CoV-2, the virus that causes COVID-19. 
Our editors will review what you’ve submitted and determine whether to revise the article.
Virology, branch of microbiology that deals with the study of viruses.
Although diseases caused by viruses have been known since the 1700s and cures for many were (somewhat later) effected, the causative agent was not closely examined until 1892, when a Russian bacteriologist, D. Ivanovski, observed that the causative agent (later proved to be a virus) of tobacco mosaic disease could pass through a porcelain filter impermeable to bacteria. Modern virology began when two bacteriologists, Frederick William Twort in 1915 and Félix d’Hérelle in 1917, independently discovered the existence of bacteriophages (viruses that infect bacteria).
Direct visualization of viruses became possible after the electron microscope was introduced about 1940. In 1935 tobacco mosaic virus became the first virus to be crystallized in 1955 the poliomyelitis virus was crystallized. (A virus “crystal” consists of several thousand viruses and, because of its purity, is well suited for chemical studies.) Virology is a discipline of immediate interest because many human diseases, including smallpox, influenza, the common cold, and AIDS, as well as a host of economically important plant and animal diseases, are caused by viruses.
Our editors will review what you’ve submitted and determine whether to revise the article.
Gestation, in mammals, the time between conception and birth, during which the embryo or fetus is developing in the uterus. This definition raises occasional difficulties because in some species (e.g., monkeys and man) the exact time of conception may not be known. In these cases the beginning of gestation is usually dated from some well-defined point in the reproductive cycle (e.g., the beginning of the previous menstrual period).
The length of gestation varies from species to species. The shortest known gestation is that of the Virginian opossum, about 12 days, and the longest that of the Indian elephant, about 22 months. In the course of evolution the duration of gestation has become adapted to the needs of the species. The degree of ultimate growth is a factor, smaller animals usually having shorter periods of gestation than larger ones. Exceptions are the guinea pig and related South American rodents, in which gestation is prolonged (averaging 68 days for the guinea pig and 111 days for the chinchilla). The young of these species are born in a state of greater maturity than are those of the rat with its period of 22 days. Another factor is that, in many species with restricted breeding seasons, gestation is adjusted so that birth coincides with the period when food is most abundant. Thus the horse, a spring breeder with 11 months’ gestation, has its young the following spring, as does the sheep, a fall breeder with a five months’ gestation. Animals that live in the open tend to have longer gestations and to bear young that have reached a state of greater maturity than do animals that can conceal their young in underground burrows or in caves. Marsupials generally have short gestations—e.g., 40 days for the largest kangaroos. The young, born in an extremely immature state, transfer to the pouch in which gestation may be said to continue.
Embryos of some species experience an arrest in development that greatly prolongs gestation. This is especially true of the fur-bearing carnivores the martens and weasels. Embryos of the European badger and American marten, which breed in July and August, develop for a few days, then lie dormant in the uterus, being implanted in January. Birth occurs in March. Of the total gestation period of 250 days, growth occurs during only 50. Delayed implantation also occurs in mice and other small rodents that become pregnant while they are still suckling a litter.
Either a single factor or a great number of minor factors, all culminating at or near one date, determine the length of gestation. Several minor variations are known: in man, gestation for males is three to four days longer than that for females and in cattle, bulls are carried about one day longer than heifers. In both species gestation of twins is five to six days less than for singlets. In animals such as the rabbit or pig, which bear many young at a time, gestation is shorter for larger litters than for smaller ones. Heredity also influences gestation in cattle the mean gestation period for Holstein-Friesians is 279 days for Brown Swiss, 290 days other breeds fall between these extremes. When hybrids are produced by crossing two species with different gestation periods, the hybrid is carried for a period lying somewhere between those of the two parents and tending toward the mother’s species. Thus a mare carries a mule foal (fathered by a jackass) about 10 days longer than the normal period for the horse (about 337 days). For human gestation, see pregnancy.
Early cloning experiments
Reproductive cloning was originally carried out by artificial “twinning,” or embryo splitting, which was first performed on a salamander embryo in the early 1900s by German embryologist Hans Spemann. Later, Spemann, who was awarded the Nobel Prize for Physiology or Medicine (1935) for his research on embryonic development, theorized about another cloning procedure known as nuclear transfer. This procedure was performed in 1952 by American scientists Robert W. Briggs and Thomas J. King, who used DNA from embryonic cells of the frog Rana pipiens to generate cloned tadpoles. In 1958 British biologist John Bertrand Gurdon successfully carried out nuclear transfer using DNA from adult intestinal cells of African clawed frogs (Xenopus laevis). Gurdon was awarded a share of the 2012 Nobel Prize in Physiology or Medicine for this breakthrough.
Advancements in the field of molecular biology led to the development of techniques that allowed scientists to manipulate cells and to detect chemical markers that signal changes within cells. With the advent of recombinant DNA technology in the 1970s, it became possible for scientists to create transgenic clones—clones with genomes containing pieces of DNA from other organisms. Beginning in the 1980s mammals such as sheep were cloned from early and partially differentiated embryonic cells. In 1996 British developmental biologist Ian Wilmut generated a cloned sheep, named Dolly, by means of nuclear transfer involving an enucleated embryo and a differentiated cell nucleus. This technique, which was later refined and became known as somatic cell nuclear transfer (SCNT), represented an extraordinary advance in the science of cloning, because it resulted in the creation of a genetically identical clone of an already grown sheep. It also indicated that it was possible for the DNA in differentiated somatic (body) cells to revert to an undifferentiated embryonic stage, thereby reestablishing pluripotency—the potential of an embryonic cell to grow into any one of the numerous different types of mature body cells that make up a complete organism. The realization that the DNA of somatic cells could be reprogrammed to a pluripotent state significantly impacted research into therapeutic cloning and the development of stem cell therapies.
Soon after the generation of Dolly, a number of other animals were cloned by SCNT, including pigs, goats, rats, mice, dogs, horses, and mules. Despite those successes, the birth of a viable SCNT primate clone would not come to fruition until 2018, and scientists used other cloning processes in the meantime. In 2001 a team of scientists cloned a rhesus monkey through a process called embryonic cell nuclear transfer, which is similar to SCNT except that it uses DNA from an undifferentiated embryo. In 2007 macaque monkey embryos were cloned by SCNT, but those clones lived only to the blastocyst stage of embryonic development. It was more than 10 years later, after improvements to SCNT had been made, that scientists announced the live birth of two clones of the crab-eating macaque (Macaca fascicularis), the first primate clones using the SCNT process. (SCNT has been carried out with very limited success in humans, in part because of problems with human egg cells resulting from the mother’s age and environmental factors.)
S1 Fig. Cloning of MoSMP30 into Vector pET28 a (+).
Agaroge gel images showing (A) the PCR amplified product of MoSMP30 gene, band size 879 bp, (B) confirmation of MoSMP30 gene cloning in pJET1.2 vector by restriction digestion, (C) preparation of vector by restriction digestion of the pET28 a (+) plasmid, and (D) confirmation of MoSMP30 gene cloning in pET28a vector by restriction digestion.
S2 Fig. Cloning of HuSMP30 into pET28 a (+) vector.
Agarose gel images showing (A) restriction digested HuSMP30 product with the restriction enzymes Nde1 and Xho1, (B) vector preparation by the restriction digestion of the pET28 a (+) plasmid, band size
5289 bp, and (C) confirmation of HuSMP30 gene cloning in pET28a vector by restriction digestion.
S3 Fig. SDS-PAGE of MoSMP30 and HuSMP30 proteins from E. coli (BL21) strain after Coomassie brilliant blue (CBB) staining.
HuSMP30 gene was inserted into pET28a vector and transformed into E. coli (BL21) cells. The protein concentrations were estimated by the using BCA method, and an equal amounts of proteins both from supernatants and pellets were resolved on 12% SDS-PAGE. Induced supernatant, induced pellet, un-induced supernatant, un-induced pellet, and standard protein marker were loaded in lanes 1, 2, 3, 4 and M respectively. The box indicates the induction of (A) MoSMP30 and (B) HuSMP30 proteins.
S4 Fig. Purification of soluble proteins by Ni-NTA affinity chromatography.
Purification of soluble fractions of proteins and the samples collected during several elution steps were analysed by 12% SDS-PAGE gel which shows (A) elutution fractions (E1, E2, E3, E4 and E5) collected for MoSMP30 and (B) elutution fractions (E1, E2 and E3) collected for HuSMP30.
S5 Fig. Inclusion body (IB) preparation from the insoluble fractions.
12% SDS-PAGE image showing (A) the samples collected during the subsequent purification steps 1, 2, 3, 4, 5 and 6 of IBs purification for MoSMP30. Lane 7 and 9 contain dissolved inclusion body protein and protein marker (ladder) respectively and (B) the samples collected during the subsequent purification steps 1, 2, 3, 4, 5 and 6 of IBs purification for HuSMP30. Protein marker (ladder) and dissolved inclusion body proteins were loaded in lane 7 and 9 respectively.
S6 Fig. UV-VIS titration shown for HuSMP30 with Ca 2+ .
For the calculation of metal binding affinity (Kd values) with different metals, UV-VIS data were acquired at 250-500nm wavelengths. Concentration dependent shift in the delta absorbance was observed at 333nm.
S7 Fig. Calculation of Kd values for MoSMP30.
Kd values were estimated for each of the metals by fitted to Hill equation with a non-linear curve at growth/Sigmoid model using Origin Pro software. The Y-axis represents the delta A333nm and X-axis represents the different metal concentrations.
S8 Fig. Calculation of Kd values for HuSMP30.
Kd values were estimated for each of the metals by fitted to Hill equation with a non-linear curve at growth/Sigmoid model using Origin Pro software. The Y-axis represents the delta A333nm and X-axis represents the different metal concentrations.
S9 Fig. Enzyme kinetics by Lineweaver-Burk plots for the hydrolysis of GTBL.
Double reciprocal plots for the calculation of kinetic parameters (Km and Vmax) were showing concentration dependent incraese in the hydrolysis of GTBL in the presence of (A) Ca 2+ by MoSMP30, (B) Ca 2+ by HoSMP30, (C) Co 2+ by MoSMP30 and (D) Zn 2+ by HuSMP30. Y-axis showing the reciprocal reaction velocity (OD/min), and X-axis showing the reciprocal substrate concentrations (mM). The error bar shows the standard error of the mean (SEM) calculated from triplicate experiments.
S10 Fig. Enzyme kinetics by Lineweaver Burk Plots for the OP (Demeton-S) hydrolysis.
Double reciprocal plots for the calculation of kinetic parameters (Km and Vmax) in the presence of Ca 2+ and Zn 2+ were able to show the activity. MoSMP30 showing increased rate of reaction with increasing conentration of the Demeton-S in the presence of (A) Ca 2+ & (C) Zn 2+ . Similarily, HuSMP30 showing activity with (B) Ca 2+ & (D) Zn 2+ . Y-axis showing the reciprocal reaction velocity (OD/min), and X-axis showing the reciprocal substrate concentrations (mM). The error bar shows the standard error of the mean (SEM) calculated from triplicate experiments.
A content marketing guide is generic , your business needs are very much concrete.
IKEA tackles the generic -ness problem by making a vast range of different products, and periodically updating long-running bestsellers.
For example, you can use generic keywords to describe your business, your product, and your services.
Instead, its goal is to shore up the US supply of generic drugs.
Metformin is a widely-used generic drug for mitigating liver sugar production in Type 2 diabetes patients.
And with sildenafil citrate going generic in three years, Pfizer will soon lose sole ownership over the Viagra formula.
But here we are at a generic hotel suite in downtown Toronto.
But everything in Abbudin feels willfully generic , as if even the tiniest hint of specificity might give offense.
We could have made the production a bit more 2010s by steering it in a more generic direction.
Ketorolac, a generic , is considered a relatively nontoxic drug.
Mangold is here, then, a generic term, standing for other plants equally with the beet.
Illiger (1811:83) proposed Tamias as the generic name of the chipmunk of eastern North America.
We have also some portraits of Miss Vaughan, who is aggressive and good to look at but this is not the generic distinction.
We shall first distinguish them by the two generic names of Sapajous and Sagoins.
The word guma, like aubo, appears to be a generic term for water, or potable liquids.
Protein binding: what does it mean?
Protein binding can enhance or detract from a drug's performance. As a general rule, agents that are minimally protein bound penetrate tissue better than those that are highly bound, but they are excreted much faster. Among drugs that are less than 80-85 percent protein bound, differences appear to be of slight clinical importance. Agents that are highly protein bound may, however, differ markedly from those that are minimally bound in terms of tissue penetration and half-life. Drugs may bind to a wide variety of plasma proteins, including albumin. If the percentage of protein-bound drug is greater when measured in human blood than in a simple albumin solution, the clinician should suspect that the agent may be bound in vivo to one of these "minority" plasma proteins. The concentration of several plasma proteins can be altered by many factors, including stress, surgery, liver or kidney dysfunction, and pregnancy. In such circumstances, free drug concentrations are a more accurate index of clinical effect than are total concentrations. Formulary committees must grasp the clinical significance of qualitative and quantitative differences in protein binding when evaluating competing agents.